FilingSEC EDGAR8-K
Relmada Therapeutics CMO Departs
· SEC accepted
StageN/A
Filing content
Dr. Raj S. Pruthi, Chief Medical Officer of Relmada Therapeutics, Inc., ended his employment on September 3, 2026.
AI summary of the filing. Please also check the source.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…